Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.

@article{Wire2012AssessmentOT,
  title={Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.},
  author={Mary Beth Wire and Heidi B McLean and Carolyn Pendry and Dickens Theodore and Jung Wook Park and Bin Peng},
  journal={Antimicrobial agents and chemotherapy},
  year={2012},
  volume={56 6},
  pages={
          2846-51
        }
}
Eltrombopag is an orally bioavailable thrombopoietin receptor agonist that is approved for the treatment of chronic idiopathic thrombocytopenic purpura. It is being developed for other medical disorders that are associated with thrombocytopenia. Patients with human immunodeficiency virus (HIV) may suffer from thrombocytopenia as a result of their HIV disease or coinfection with hepatitis C virus (HCV). HIV medications, particularly ritonavir (RTV)-boosted HIV protease inhibitors, are involved… CONTINUE READING

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.

  • British journal of clinical pharmacology
  • 2011
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Effect of an antitretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6, and P-glycoprotein in HIV-infected patients

C Wyen
  • Clin. Pharmacol. Ther
  • 2008
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL